Jacob Lalezari

Statistics

Publications

108

Citations

13.5K

H-Index

Active since

1994

Affiliations

Quest Clinical Research (United States)(Current)

University of California, San Francisco

Gilead Sciences (United States)

Johns Hopkins University

Community Research Initiative

Jacob Lalezari is an author at Quest Clinical Research (United States) specializing in antiviral therapy, antiviral pharmacotherapy, and antiviral pharmacology.

ORCID

Publications per year

1994–2023

108

Publications

108

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

Nezam H. Afdhal, K. Rajender Reddy, David R. Nelson et al. · New England Journal of Medicine · 2014 · 1.3K citations

Medicine, Infectious Diseases, Microbiology +12

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

Jacob Lalezari, Keith Henry, Mary O’Hearn et al. · New England Journal of Medicine · 2003 · 915 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacotherapy +16

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Roy M. Gulick, Jacob Lalezari, James Goodrich et al. · New England Journal of Medicine · 2008 · 741 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Péter Ferenci, David Bernstein, Jacob Lalezari et al. · New England Journal of Medicine · 2014 · 695 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

David R. Nelson, James N. Cooper, Jacob Lalezari et al. · Hepatology · 2015 · 689 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

1–5 of 108